TRUALT BIOENERGY LIMITED (TRUALT) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of TRUALT BIOENERGY LIMITED ₹158, price ₹444, upside -64.4%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch TRUALT BIOENERGY LIMITED for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 2, 2026.
How to read this chart
12‑month range ₹319.65 – ₹531.95 · fair‑value band ₹131.91 – ₹197.69 · the ₹444.30 price screens above the ₹158.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 2, 2026.
Follow TRUALT BIOENERGY in your weekly email
Every Wednesday you see whether TRUALT BIOENERGY is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TruAlt Bioenergy Limited produces and sells biofuels in India. Its products include ethanol, compressed biogas, extra neutral alcohol, and fermented organic manure. The company was formerly known as TruAlt Energy Limited and changed its name to TruAlt Bioenergy Limited in July 2022.
Show more
TruAlt Bioenergy Limited produces and sells biofuels in India. Its products include ethanol, compressed biogas, extra neutral alcohol, and fermented organic manure. The company was formerly known as TruAlt Energy Limited and changed its name to TruAlt Bioenergy Limited in July 2022. TruAlt Bioenergy Limited was incorporated in 2021 and is based in Bengaluru, India.
Stock analysis
TRUALT BIOENERGY LIMITED (TRUALT) currently trades at ₹444.30, while our model-based Fair Value estimate is ₹158.15, 64.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹197.94 per share, and 0 of the 14 models we run sit above the ₹444.30 price.
Bear case: the Economic Profit group reads lowest at ₹65.45, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ₹131.91 (bear) to ₹197.69 (bull), the price of ₹444.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Energy sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
TRUALT BIOENERGY LIMITED reported revenue of ₹17.3B in FY2026 versus ₹7.0B in FY2022, a compound +25.5%/yr. Reported net income was ₹969M in FY2026, compounding +26.7%/yr from FY2022.
Key figures
Market cap ₹38.1B (≈ $396M) · P/E ratio 27.1 · P/S ratio 1.52 · EPS (TTM) ₹16.39 · Net margin 5.6% · Return on equity 8.3% · Return on assets (EBIT) 6.7% · Operating margin 17.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Energy peers we cover trades at −66% fair-value upside, at −64%, TRUALT screens cheaper than that median.
Fair Value models
Bear ₹131.91Fair Value ₹158.15Bull ₹197.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹8.31 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.46/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−9.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.2%
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.1% (2022) → 11.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 2 usable fiscal years, at least 4 required
Compare TRUALT BIOENERGY LIMITED with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas Refining & Marketing · 103 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score28 · Bottom 25%
Fair Value upside−64.4% · Bottom 25%
Profitability
Return on equity (TTM)8.3% · Below median
Return on assets3.7% · Below median
Net margin (TTM)7.2% · Top 25%
Operating margin (TTM)17.2% · Top 25%
Growth and dividend
Revenue growth106.3% · Top 25%
Balance sheet
Debt / equity0.65× · Above median
Valuation Multiplesvs Oil & Gas Refining & Marketing median · lower = cheaper
P/E (TTM)27.1× · Priciest 25%
P/B2.51× · Priciest 25%
P/S (TTM)1.86× · Priciest 25%
EV/EBITDA12.3× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)100· sector 100
PAST (return on equity)33· sector 51
HEALTH (low debt)68· sector 85
DIVIDEND (yield)0· sector 67
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is TRUALT BIOENERGY LIMITED (TRUALT) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ₹158.15 versus a price of ₹444.30, about −64% upside (overvalued).
What is the fair value of TRUALT?
Our model-based fair value for TRUALT BIOENERGY LIMITED is ₹158.15 (as of Oct 2, 2026), built from audited fundamentals. The current price: ₹444.30.
What is the quality score of TRUALT?
TRUALT BIOENERGY LIMITED has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TRUALT BIOENERGY LIMITED (TRUALT)?
Our model-based price target is the fair value of ₹158.15 (as of Oct 2, 2026) from 14 valuation models. Cautious scenario ₹131.91, optimistic scenario ₹197.69. It is a calculation from audited fundamentals, not an analyst target.
What is the TRUALT BIOENERGY LIMITED stock forecast for 2026?
Our models put fair value at ₹158.15, about −64% upside versus a price of ₹444.30 (overvalued). Cautious scenario ₹131.91, optimistic scenario ₹197.69. The calculation is refreshed regularly with new filings.
What is the revenue of TRUALT BIOENERGY LIMITED (TRUALT)?
TRUALT BIOENERGY LIMITED reported trailing-twelve-month revenue of about ₹20.5B (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of TRUALT BIOENERGY LIMITED (TRUALT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TRUALT BIOENERGY LIMITED it is ₹158.15 per share (as of Oct 2, 2026), against a price of ₹444.30. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is TRUALT BIOENERGY LIMITED stock overvalued or undervalued in 2026?
As of Oct 2, 2026, TRUALT trades above its calculated fair value: price ₹444.30, fair value ₹158.15, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TRUALT?
No. The price is what the market pays today (₹444.30); the fair value is what the company's own numbers justify (₹158.15). For TRUALT BIOENERGY LIMITED the two are ₹286.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is TRUALT BIOENERGY LIMITED worth?
The market values TRUALT BIOENERGY LIMITED at about ₹38.1B (market capitalisation, as of Oct 2, 2026). Per share that is ₹444.30; our models calculate a fair value of ₹158.15 per share.
What do the bullish and bearish scenarios say about TRUALT?
Our models span a range for TRUALT BIOENERGY LIMITED: cautious scenario ₹131.91, base ₹158.15, optimistic ₹197.69 per share (as of Oct 2, 2026, price ₹444.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TRUALT?
TRUALT BIOENERGY LIMITED trades at a price-to-earnings ratio of 27.1 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹158.15 is built from several models across several years. Other multiples: P/B 2.5, P/S 1.9, EV/EBITDA 12.3.
How solid is the balance sheet of TRUALT BIOENERGY LIMITED (TRUALT)?
Balance-sheet figures for TRUALT BIOENERGY LIMITED (as of Oct 2, 2026): return on equity 8.3%, debt of 0.65 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is TRUALT from its 52-week high?
TRUALT BIOENERGY LIMITED trades at ₹444.30, about 16% below its 52-week high of ₹531.95 and 39% above the low of ₹319.65 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹158.15 is for.
Which stocks are comparable to TRUALT BIOENERGY LIMITED?
From the same area (Energy) we also value Reliance Industries Limited, Valero Energy Corporation, Marathon Petroleum Corporation, Phillips 66, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TRUALT BIOENERGY LIMITED stock attractive at the current price?
The data as of Oct 2, 2026: price ₹444.30, calculated fair value ₹158.15 (−64%), Quality Score 28/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TRUALT calculated?
We run TRUALT BIOENERGY LIMITED through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹158.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. TRUALT BIOENERGY LIMITED itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TRUALT BIOENERGY LIMITED (TRUALT)?
The closing price on Oct 1, 2026 was ₹444.30. Our model-based fair value is ₹158.15, about −64% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TRUALT BIOENERGY LIMITED right now?
The price sits above even our optimistic bull case (₹197.69). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of TRUALT BIOENERGY LIMITED
How large is the market capitalisation of TRUALT BIOENERGY LIMITED (TRUALT)?
The market capitalisation of TRUALT BIOENERGY LIMITED is ₹38.1B (≈ $396M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TRUALT BIOENERGY LIMITED (TRUALT)?
The price-to-sales ratio of TRUALT BIOENERGY LIMITED is 1.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TRUALT BIOENERGY LIMITED (TRUALT)?
Earnings per share at TRUALT BIOENERGY LIMITED are ₹16.39 (price ÷ EPS = P/E 27.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TRUALT BIOENERGY LIMITED (TRUALT)?
The net margin of TRUALT BIOENERGY LIMITED is 5.6% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TRUALT BIOENERGY LIMITED (TRUALT)?
The return on equity (ROE) of TRUALT BIOENERGY LIMITED is 8.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TRUALT BIOENERGY LIMITED (TRUALT)?
On an EBIT basis the return on assets of TRUALT BIOENERGY LIMITED is 6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TRUALT BIOENERGY LIMITED (TRUALT)?
The operating margin of TRUALT BIOENERGY LIMITED is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TRUALT BIOENERGY LIMITED (TRUALT)?
Revenue at TRUALT BIOENERGY LIMITED is growing +106% versus a year earlier (3y avg +14.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TRUALT BIOENERGY LIMITED (TRUALT)?
Earnings per share at TRUALT BIOENERGY LIMITED are growing +896% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does TRUALT BIOENERGY LIMITED (TRUALT) generate?
The free cash flow of TRUALT BIOENERGY LIMITED is −₹8.1B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does TRUALT BIOENERGY LIMITED (TRUALT) carry?
The net debt of TRUALT BIOENERGY LIMITED is ₹15.6B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch TRUALT BIOENERGY LIMITED in the live analysis
One click puts TRUALT BIOENERGY LIMITED on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
